Holen Sie sich die Stockscreener-App
0.95
7.77%
-0.08
Handel nachbörslich:
1.00
0.05
+5.26%
Schlusskurs vom Vortag:
$1.03
Offen:
$1.02
24-Stunden-Volumen:
224.32K
Relative Volume:
0.90
Marktkapitalisierung:
$72.05M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-1.7925
EPS:
-0.53
Netto-Cashflow:
$-19.91M
1W Leistung:
-11.21%
1M Leistung:
+3.03%
6M Leistung:
-5.94%
1J Leistung:
-26.92%
1-Tages-Spanne:
$0.95
$1.02
1-Wochen-Bereich:
$0.95
$1.09
52-Wochen-Spanne:
$0.801
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Vergleichen Sie CLSD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.95 | 72.05M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - MSN
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, - GlobeNewswire
China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market? - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Clearside reports progress in wet AMD treatment trials - MSN
Clearside Biomedical Announces Additional Data from the - GlobeNewswire
Clearside reports progress in wet AMD treatment trials By Investing.com - Investing.com Nigeria
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat
Selling Your Clearside Biomedical Inc (CLSD) Stock? Here’s What You Need To Know - Stocks Register
Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - The Manila Times
Clearside Biomedical to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Nasdaq
Clearside Biomedical to Participate in Fireside Chat at the - GlobeNewswire
Inside Clearside Biomedical's Strategic Vision: CEO Fireside Chat at Major Healthcare Conference - StockTitan
Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences - Nasdaq
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - GlobeNewswire
Clearside Biomedical Announces Multiple Medical Meeting - GlobeNewswire
Revolutionary Eye Treatment Could Replace Monthly Injections for AMD Patients - StockTitan
Assenagon Asset Management S.A. Sells 125,190 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical Announces its Asia-Pacific Partner, - GlobeNewswire
Clearside's ARCATUS Eye Treatment Wins Historic First Approvals in Australia, Singapore - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Geode Capital Management LLC Buys 59,089 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Below 50-Day Moving Average – Here’s Why - Defense World
Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72% - Simply Wall St
Clearside Biomedical stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Clearside Biomedical stock hits 52-week low at $0.92 - Investing.com
Clearside announces publication of insights on drug development, regulation - Yahoo Finance
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock - GuruFocus.com
Clearside Biomedical Announces Publication of Critical - GlobeNewswire
Clearside Biomedical Unveils Groundbreaking Insights on Retinal Drug Development in Eye Journal - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.33 - MarketBeat
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now - MSN
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in November - MarketBeat
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):